Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2022 | Story Andrè Damons | Photo Andrè Damons
Prof Motlalepula Matsabisa
This week, Prof Motlalepula Matsabisa, will give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

Prof Motlalepula Matsabisa, Director of Pharmacology at the University of the Free State (UFS), has been invited to give a keynote speech on Indigenous Knowledge Systems (IKS) and Health during a session at the eighth edition of the UNGA77 Science Summit around the 77th United Nations General Assembly (SSUNGA77).

While in New York, Prof Matsabisa will also meet with officials from the Wellcome Trust – a global charitable foundation – where he will present a strong and compelling motivation for the Wellcome Trust to invest in traditional medicines. Says Prof Matsabisa: “I will deliver a compelling message for investment to be made in scientific research and development around traditional medicines. This development will be piloted in a hub-and-spoke model based on the African economic blocks, with the hub being in South Africa. The returns on the investment put in this initiative will be massive for the African continent, both socially and economically, and I believe it will lead to self-sustainability and Africa being a supplier of innovations based on the science of traditional medicines.” 

SSUNGA77 is organised by Intelligence in Science and will take place from 13 to 30 September 2022. It will bring together thought leaders, scientists, technologists, innovators, policy makers, decision makers, regulators, financiers, philanthropists, journalists and editors, and community leaders to increase health science and citizen collaboration across a broad spectrum of themes, including ICT, nutrition, agriculture, health, IKS, and the environment.

Prof Matsabisa, an expert in African traditional medicine (ATM) and Chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19 (REACT), is also the convener of this session, following his successful proposal for such a session. The session will take place in person on 20 September at the UN headquarters in New York. It is an official side event of the UN General Assembly’s 77th anniversary and will be co-sponsored by the permanent missions of Ireland, Spain, South Africa, Brazil, and Bangladesh to the UN.

His message at Science Summit

“At the end of the summit, we are to make recommendations to the UN, EU, and AU on IKS and health developmental matters. This is exciting and nerve-wracking for me, but I will remain calm knowing that I have a message to deliver to the highest global decision-making body. There can be nothing greater than presenting my talk and proposals for consideration to such a body.” 

“I will convey three simple messages, namely the importance of traditional medicines in contributing to universal health coverage, the need for Africa – through the heads of state and governments – to take seriously the local manufacturing of traditional medicines for industrialisation, economic emancipation, and responding to poverty and inequality. The third message is the need for sustained and adequate financial support by African ministries of health for the development, commercialisation, and market access to quality and well-researched, safe, and effective traditional medicines in order to contribute to priority diseases as well as responding to pandemics,” says Prof Matsabisa. 

According to him, this address at SSUNGA77 is a chance to correctly position the story on IKS with arguments based on good scientific evidence. “It means we are getting much closer to the institutionalisation and formal economic contribution of IKS to health, and that the African IKS health system is getting international recognition and acceptance,” he says.
Prof Matsabisa says he hopes the message will emerge clearly from his talk that Africa has the resources for raw materials and that the science, as well as the infrastructure, exists to develop IKS and to contribute to new health products. The spin-off is the industrialisation, job creation, and wealth generation that Africa can offer to the rest of the world.

Overall information on the summit is available here

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept